ResultsIQ › Latest results › Bharat Parenterals Limited
Bharat Parenterals Limited Q2 FY27 earnings call summary
NSE: BPLPHARMA · BSE: 541096
Earnings call of 30 Oct 2026, summarised by AI from the filing.
Bharat Parenterals swung to a consolidated PAT of ₹11.8 cr in Q2 FY27 as Innoxel reached a 33% EBITDA margin and FY27 guidance was maintained.
Key takeaways
- Innoxel swing Innoxel EBITDA ₹14.6 cr at 33% margin against a loss of ₹1.8 cr in Q1 FY27.
- US supply First CMO product exported to the US on 20 October 2026, moving Innoxel into recurring commercial supply.
- Input costs Rising input costs cut standalone gross margin to 35% and pressure margins on orders priced earlier.
Bharat Parenterals Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (30 Oct 2026), Results deck (29 Oct 2026)
- Q1 FY27: Results deck (5 Aug 2026)
- Q4 FY26: Earnings call (19 May 2026), Results deck (18 May 2026)
- Q3 FY26: Results deck (30 Jan 2026)
- Q2 FY26: Earnings call (12 Nov 2025), Results deck (12 Nov 2025)
- Q1 FY26: Results deck (28 Jul 2025)
- Q4 FY25: Earnings call (14 May 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.